Compare 10X Genomics Inc (TXG) vs Western Alliance Bancorporation (WAL) Price & Performance

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.

Western Alliance Bancorporation (WAL) trades at $79.94, down 1.25% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 8.99, net income margin of 25.43%, and recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX, an institutional financial platform, and recognition as Arizona's #1 best bank by Forbes in 2026.

The outlook is positive with a consensus price target of $93.86, implying 17% upside, supported by 79% analyst buy ratings. Risks include negative operating cash flow in 2025 and competitive pressures in the banking sector. Earnings growth and institutional investments remain key catalysts for potential appreciation.